# US 2008/0188483 A1 · Compounds and Compositions as Protein Kinase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188483 A1
- Document ID: US20080188483A1
- Status: Published application
- Kind: A1
- Application number: 11/817,951
- Filed: 2006-03-10
- Published: 2008-08-07
- Earliest claimed: 2006-03-10
- Assignees: Irm LLC
- Inventors: Pingda Ren; Nathanael Schiander Gray; Xia Wang; Guobao Zhang
- Web page: https://patentgrep.com/patent/US20080188483A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK2α2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFRβ, PKA, PKBβ, PKD2, Rsk1, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB kinases.

## Claims

### Claim 1

A compound of Formula I:
in which:
n is selected from 0, 1, 2, 3 and 4;
Z1 is selected from N, C(O) and CR3; wherein R3 is selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, halo-substituted-C1-4alkoxy, C6-12aryl, C5-8heteroaryl, C3-12cycloalkyl, C3-8heterocycloalkyl and NR5R6; wherein R5 is independently selected from hydrogen and C1-4alkyl; and R6 is selected from hydrogen, C1-4alkyl and C6-12aryl; and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R3 is optionally substituted with 1 to 3 radicals independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy;
Z2 is selected from N and CR4; wherein R4 is selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, halo-substituted-C1-4alkoxy, C6-12aryl, C5-8heteroaryl, C3-12cycloalkyl, C3-8heterocycloalkyl and NR5R5; and wherein the bond between Z1 and Z2 is selected from a single bond and a double bond; R5 is independently selected from hydrogen and C1-4alkyl; and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R4 is optionally substituted with 1 to 3 radicals independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy;
R1 is selected from halo, C1-4alkyl and C1-4alkoxy;
R2 is selected from NR5C(O)NR5R6, NR5C(O)R6, C(O)NR5R6, NR5S(O)0-2R6, S(O)0-2NR5R6 and NR5R6; wherein R5 is independently selected from hydrogen and C1-4alkyl; and R6 is selected from hydrogen, C1-4alkyl, C6-12aryl, C5-8heteroaryl, C3-12cycloalkyl and C3-8heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R6 is optionally substituted by 1 to 3 radicals independently selected from halo, cyano, nitro, halo-substituted-C1-4alkyl, halo-substituted-C1-4alkoxy, C5-12heteroaryl-C0-4alkyl and C3-12heterocycloalkyl-C0-4alkyl; wherein any heteroaryl or heterocycloalkyl substituents of R6 can optionally be substituted by a radical independently selected from C1-4alkyl and C3-12heterocycloalkyl; and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof.

### Claim 2 (depends on 1)

The compound of claim 1 in which:
n is selected from 1, 2, 3 and 4;
Z1 is selected from N, C(O) and CH;
Z2 is selected from N and CR4; wherein R4 is selected from hydrogen and halo; and wherein the bond between Z1 and Z2 is selected from a single bond and a double bond;
R1 is selected from C1-4alkyl and C1-4alkoxy;
R2 is selected from NR5C(O)R6, C(O)NR5R6 and NR5R6; wherein R5 is independently selected from hydrogen and C1-4alkyl; and R6 is selected from hydrogen, C1-4alkyl and C6-12aryl; wherein any aryl of R6 is optionally substituted by 1 to 3 radicals independently selected from halo-substituted-C1-4alkyl, C5-12heteroaryl-C0-4alkyl and C3-12heterocycloalkyl-C0-4alkyl; wherein any heteroaryl or heterocycloalkyl substituents of R6 can optionally be substituted by a radical independently selected from C1-4alkyl and C3-12heterocycloalkyl; and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof.

### Claim 3 (depends on 1)

The compound of claim 1 selected from: N-{3-[1-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide; 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-[1-(9H-purin-6-yl)-1H-imidazol-2-ylamino]-benzamide; 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-[1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-benzamide; N-{4-Methyl-3-[1-(6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-3-trifluoromethyl-benzamide; N-{4-Methyl-3-[1-(9H-purin-6-yl)-1H-imidazol-2-ylamino]-phenyl}-3-trifluoromethyl-benzamide; and N-{4-Methyl-3-[1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-3-trifluoromethyl-benzamide.

### Claim 4 (depends on 1)

The compound of claim 1 of Formula Ia:
in which:
R1 is selected from methyl and methoxy;
R2 is selected from NHC(O)R6, C(O)NHR6 and NHR6; wherein R6 is selected from hydrogen, methyl and phenyl; wherein any phenyl of R6 is optionally substituted by 1 to 3 radicals independently selected from trifluoromethyl, imidazolyl, piperidinyl, piperazinyl and piperazinyl-methyl; wherein any heteroaryl or heterocycloalkyl substituents of R6 can optionally be substituted by a radical independently selected from methyl, ethyl and pyrrolidinyl.

### Claim 5 (depends on 4)

The compound of claim 4 selected from: 4-Methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-benzamide; 3-(4-methyl-imidazol-1-yl)-N-{4-methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-5-trifluoromethyl-benzamide; 4-(4-Methyl-piperazin-1-ylmethyl)-N-{4-methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-3-trifluoromethyl-benzamide; 3-(4-Ethyl-piperazin-1-ylmethyl)-N-{4-methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-5-trifluoromethyl-benzamide; N-{4-Methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-3-(4-pyrrolidin-1-yl-piperidin-1-yl)-5-trifluoromethyl-benzamide; 3-Methoxy-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-5-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-benzamide; 3-(4-Methyl-imidazol-1-yl)-N-{4-methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-5-trifluoromethyl-benzamide; 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-benzamide; N-[4-(4-Ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-3-methoxy-5-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-benzamide; N-[4-(4-Ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-4-methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-benzamide; 3-(4-Ethyl-piperazin-1-yl)-N-{4-methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-5-trifluoromethyl-benzamide; 3-[1-(5-Fluoro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-4-methyl-N-(3-trifluoromethyl-phenyl)-benzamide; N-{4-Methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-3-trifluoromethyl-benzamide; 4-Methyl-N-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-phenyl]-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-benzamide; N-{3-[1-(5-Chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide; N-{4-Methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-benzamide; N-{4-Methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-acetamide; 4-Methyl-N3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-yl]-benzene-1,3-diamine; and 3-(4-Methyl-piperazin-1-yl)-N-{4-methyl-3-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-imidazol-2-ylamino]-phenyl}-5-trifluoromethyl-benzamide.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable excipient.

### Claim 7 (depends on 1)

A method for treating a disease in an animal in which inhibition of kinase activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of claim 1.

### Claim 8 (depends on 5)

The method of claim 5 in which the kinase is selected from Abl, Bcr-Abl, BMX, BTK, CHK2, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK2α2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFRβ, PKA, PKBα, PKD2, Rsk1, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB.

### Claim 9 (depends on 1)

The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which the kinase activity of Abl, Bcr-Abl, BMX, BTK, CHK2, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK2α2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFRβ, PKA, PKBα, PKD2, Rsk1, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB contributes to the pathology and/or symptomology of the disease.
